Date:9/8/2009

nts expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to continue to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

    Company Contact:                          Investor Relations Contact:
    Senesco Technologies, Inc.                FD
    Bruce Galton                              Brian Ritchie
    Chief Executive Officer                   (brian.ritchie@fd.com)
    (bgalton@senesco.com)                     (212) 850-5600
    (732) 296-8400

'/>"/>

SOURCE Senesco Technologies, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
2. Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing
3. ArborGen and Senesco Announce Wood Quality Results
4. Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors
5. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
6. Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results
7. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
8. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
9. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
10. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience